Outcomes of Unselected Patients with Metastatic Clear-Cell Renal Cell Carcinoma Treated with Front-Line Pazopanib Therapy Followed by Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors (VEGFR-TKI) or Mammalian Target of Rapamycin Inhibitors (mTORi): A Single Institution Experience

BACKGROUND: Data regarding unselected patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with first-line pazopanib are limited. PATIENTS AND METHODS: We reviewed records of patients with metastatic ccRCC treated with first-line pazopanib during 11/09-11/12. Cox models were fitt...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BJU Int
Auteurs principaux: Matrana, Marc R., Bathala, Tharakeswara, Campbell, Matthew T, Duran, Cihan, Shetty, Aditya, Teegavarapu, Purnima, Kalra, Sarathi, Xiao, Lianchun, Atkinson, Bradley, Corn, Paul, Jonasch, Eric, Tannir, Nizar M
Format: Artigo
Langue:Inglês
Publié: 2015
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4870151/
https://ncbi.nlm.nih.gov/pubmed/26573089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bju.13374
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires